Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Tuesday 03rd November 2026. at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and half year ....

BIOGEN PHARMACHEM INDUSTRIES LIMITED CIN NO: L51100GJ1995PLC026702 (Formerly Known as SUN TECHNO OVERSEAS LIMITED) Date.:03.11.2026 Department of Corporate Services BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 Ref: Scrip Code: 531752 Scrip ID: BIOGEN Dear Sir / Madam, Subject: Outcome of Board Meeting held on 03rd November 2026. Ref: Regulation 33 read with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations") Pursuant to Second proviso to Regulation 30(6) and Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 we hereby inform you that the Board of Directors of the Company, in their meeting held on today i.e. Tuesday 03rd November 2026. at the Registered Office of the Company and transacted the following major businesses: 1.) Considered and approved Un-audited financial results for the quarter and half year ended as on 30th September, 2026. The board meeting commented at 02:30 PM and concluded at 03:00 PM Please take the above intimation in your records. Thanking You. Yours Faithfully, FOR, BIOGEN PHARMACHEM INDUSTRIES LIMITED KELASH BUNKAR WHOLE TIME DIRECTOR DIN: 10911360 Registered Office Address: Shop No. 8, First Floor, Makers – 1 Building, Jawahar Road, Rajkot-360001 E mail biogenpharmachem@gmail.com Biogen Pharmachem Industries Limited CIN:- L65910GJ1995PLC026702 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 Email:- suntechnooverseas@gmail.com Statement of Audited Financial Results for the Quarter & Half Year Ended September 30, 2026 Quarter Ended Six Months Ended (Rs. In lacs) Year Ended 31 Sl no. Particulars 30-Sep-26 30-Jun-26 30-Sep-25 30-Sep-26 30-Sep-25 Mar 2026 (Refer Notes Below) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1 INCOME (a) Revenue From Operation - - - - - - (b) Other Income 28.33 44.34 (10.49) 72.67 143.79 255.80 Total Income from Operations (Net) 28.33 44.34 (10.49) 72.67 143.79 255.80 2 EXPENSES - (a) Cost of material consumed - - - - - - (b) Changes in inventories of finished goods, work-in-progress, - - - - - - and stock-in-trade (c) Employee benefit expense 1.36 2.28 5.13 3.63 11.46 2 8.28 (d) Finance Costs - - - - - - (e) Depreciation and amortization expense - - - - - (f) Other expenses(Any item exceeding 10% of the total expenses relating to continuing 1.25 19.92 33.54 21.17 47.01 1 31.85 operations to be shown separately) Total Expenses 2.61 22.20 38.67 24.80 58.47 1 60.13 3 Profit / (Loss) from operations before exceptional items 25.73 22.14 ( 49.15) 47.87 85.33 9 5.67 Tax (1-2) 4 Exceptional Items - - - - - - 5 Profit / (Loss) before Tax (3 ± 4) 25.73 22.14 ( 49.15) 47.87 85.33 9 5.67 6 Tax Expense - - - - - 9 .73 7 Net Profit / (Loss) after Tax (5 - 6) 25.73 22.14 ( 49.15) 47.87 85.33 8 5.95 8 Other Comprehensive Income (net of tax ) - - - - - - 9 Total Comprehensive Income for the period (7 ± 8) 25.73 22.14 ( 49.15) 47.87 85.33 8 5.95 10 Paid-up equity share capital (Face Value of Rs.1/- each) 10,530.37 10,530.37 9,026.03 10,530.37 9,026.03 9 ,026.03 11 Other Equity - - - - - 8 82.68 12 Earnings Per Share (of Rs. 1/- each) (not annualised): (a) Basic 0.00 0.00 ( 0.01) 0.00 0.01 0 .01 (b) Diluted 0.00 0.00 ( 0.01) 0.00 0.01 0 .01 Biogen Pharmachem Industries Limited CIN:- L65910GJ1995PLC026702 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 Email:- suntechnooverseas@gmail.com (Rs. in Lakhs) Standalone Statement of Assets and Liabilities As at 30th September, 2026 As at 31st March, 2026 Particulars Un-Audited Audited A ASSETS 1 Non-current assets Property, plant and equipment - - Capital work-in-progress - - Other intangible assets - - Investments in subsidiaries, associates and joint ventures - - Financial assets Investments 3,049.75 3,278.23 Loans 6,750.10 6,612.97 Other financial assets - - Income Tax assets (net) - - Deferred tax assets (net) - - Other non-current assets - - Sub-total - Non-Current Assets 9,799.85 9,891.19 2 Current assets Inventories - - Financial assets Investments - - Trade receivables - - Cash and cash equivalents 1.27 32.16 Bank balances other than Cash and Cash equivalents above - - Loans, Current - - Other financial assets 16.62 16.53 Other current assets 157.83 - Assets classified as held for sale - - Sub-total - Current Assets 175.72 48.70 TOTAL - ASSETS 9,975.57 9,939.89 B EQUITY AND LIABILITIES 1 Equity Equity Share capital 10,530.37 9,026.03 Other equity (573.79) 882.68 Sub-total - Shareholders' funds 9,956.58 9,908.71 2 LIABILITIES Non-current liabilities Financial liabilities Borrowings, non-Current - - Provisions - - Income tax liabilities (net) 9.73 9.73 Other non-current liabilities - - Sub-total - Non-current liabilities 9.73 9.73 3 Current liabilities Financial liabilities Borrowings, Current - - Trade payables, Current - - Other financial liabilities - - Other current liabilities 9.27 21.45 Provisions - - Current tax liabilities (net) - - Sub-total - Current liabilities 9.27 21.45 TOTAL - EQUITY AND LIABILITIES 9,975.57 9,939.89 Biogen Pharmachem Industries Limited CIN:- L65910GJ1995PLC026702 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 Email:- suntechnooverseas@gmail.com Notes: 1 The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on November 03, 2026. 2 The Statutory Auditors have carried out a limited review of the above financial result. 3 Company has only one segment and hence no separate segment result has been given. 4 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary. 5 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 By order of the Board For, Biogen Pharmachem Industries Limited Place : Rajkot Kelash Bunkar Date : 03rd November, 2026 Wholetime Director Biogen Pharmachem Industries Limited CIN:- L65910GJ1995PLC026702 Regd. Office: Shop No. 8, First Floor, Makers - 1 Building, Jawahar Road, Rajkot - 360001 STANDALONE STATEMENT OF CASH FLOWS FOR THE HALF YEAR ENDED 30 SEPTEMBER 2026 (Rs. in Lakhs, unless otherwise stated) 30.09.2026 30.09.2025 Particulars Rupees Rupees A. CASH FLOW FROM OPERATING ACTIVITIES: Profit before tax 4 7.87 8 5.33 Adjustment For : Share of (profit)/loss from investment in partnership firm - - Depreciation/amortization on continuing operation - - Pre-operating Expense - Interest expenses - - Operating profit before working capital changes 4 7.87 8 5.33 Movement in Working Capital : Increase/(decrease) in Inventory - - Increase/(decrease) in Trade receivables - - Increase/(decrease) in Short Term Loan & Advances - - 1 .18 Increase/(decrease) in Current Liabilities - 1 2.18 0 .43 Increase/(decrease) in Trade Payable - - Increase/(decrease) in Other Current Assets - 1 57.92 - 1 29.35 Direct taxes paid (net of refunds) - Net Cash Flow from Operating Activities(A) - 1 22.24 - 4 4.78 B. CASH FLOW FROM INVESTING ACTIVITIES Investments in Equity Instruments 2 28.47 2 47.31 Purchase / Sale of Fixed Assets - - Increase/(decrease) in Long Term Loan & Advances - 1 37.13 - 9 97.66 Net Cash Flow from Invesing Activities(B) 9 1.34 - 7 50.35 C. CASH FLOW FROM FINANCING ACTIVITIES Proceed (Repayment) from long term borrowing - - Proceed (Repayment) from short term borrowing - - Proceed from Preferenital Warrants - 6 30.00 Net Cash Flow from Financing Activities(C) - 6 30.00 Net increase/(decrease) in cash & cash equivalents(A+B+C) - 3 0.89 - 1 65.13 Cash and Cash equivalents (Opening Balance) 3 2.16 2 01.63 Cash and Cash equivalents (Closing Balance) 1 .27 3 6.50 Previous year figure have been regrouped/ reclassified wherever necessary As per our report of even date For, Rishi Sekhri and Associates, For and on Behalf of the Board Chartered Accountants For, Biogen Pharm [Showing first 8,000 characters — download PDF for full document]